Orally active, selective inhibitor of EGFR tyrosine kinase (IC50
= 23 - 79 nM). Shows minimal activity against ErbB2, KDR, c-flt, PKC, MEK and ERK-2. Blocks EGFR autophosphorylation and inhibits tumor growth in mice bearing a range of human xenografts.
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
Sold for research purposes only under agreement from AstraZeneca
Other Product-Specific Information:
ZD1839 ('Iressa'), as an anticancer agent.
Baselga et al.
Antitumor effect and potentiation of cytotoxic drugs activity in human cancer cells by ZD-1839 (Iressa), an epidermal growth factor receptor-selective tyrosine kinase inhibitor.
Ciardiello et al.
Clin.Cancer Res., 2000;6:2053
Tumor penetration of gefitinib (Iressa), an epidermal growth factor receptor tyrosine kinase inhibitor.
McKillop et al.
Mol.Cancer Ther., 2005;4:641
The citations listed below are publications that use Tocris products. Selected citations for Iressa include:
Showing Results 1 - 10 of 11